Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stake Lifted by ProShare Advisors LLC

ProShare Advisors LLC increased its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 79.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,232 shares of the company’s stock after buying an additional 11,200 shares during the quarter. ProShare Advisors LLC’s holdings in Aquestive Therapeutics were worth $90,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its position in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Aquestive Therapeutics during the 4th quarter worth $44,000. PKS Advisory Services LLC acquired a new position in Aquestive Therapeutics during the 4th quarter worth $63,000. China Universal Asset Management Co. Ltd. acquired a new position in Aquestive Therapeutics during the 4th quarter worth $69,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after acquiring an additional 3,821 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on AQST. Oppenheimer began coverage on Aquestive Therapeutics in a report on Monday. They issued an “outperform” rating and a $7.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital cut their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.14.

Aquestive Therapeutics Trading Up 13.2%

Shares of AQST opened at $3.18 on Wednesday. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $5.80. The stock has a 50 day simple moving average of $2.65 and a 200-day simple moving average of $3.15. The stock has a market cap of $315.86 million, a PE ratio of -7.07 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. On average, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.